Elisabeth Diver, MD
Gynecological Oncology · Brooklyn
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 16 years
- Graduated 2010
Offices
2 locations · New York University · 5,925 clinicians in this group
Hospitals listed: NYU Langone Hospitals · Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Diver’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A149779 · Delinquent
Licence status: Delinquent · since 2017 · expires 2025-05-31 · Columbia University College of Physicians and Surgeons.
License renewal fee has not been paid. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- NYU Langone HospitalsNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of NYU Langone Health, which runs 5 hospitalsHome of Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 11.9 (10.8 to 13.2) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.56 to 0.78), Jul 2022 – Jun 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 110.18 (84.1 to 136.26) · 561 cases, Jul 2022 – Jun 2024Better than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 2.66 (1.81 to 3.51) · 16,112 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 3.24 (1.36 to 5.12) · 9,218 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.56 (1.28 to 3.83) · 9,540 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.39, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.097, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.529, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.7 (3.1 to 4.4) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 10.5 (9.1 to 12.3) · 10,521 cases, Jan 2022 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.7 to 0.8) · 6,063 cases, Jan 2024 – Dec 2024
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for NYU Langone Hospitals
Behind the star rating — Deaths: 8 better, 0 the same, 0 worse of 8 measures. Safety: 5 better, 2 the same, 1 worse of 8 measures. Readmissions: 8 better, 1 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.9 (10.8 to 13.2) · 2,678 cases | Worse | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.56 to 0.78) | Better | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 110.18 (84.1 to 136.26) · 561 cases | Better | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.66 (1.81 to 3.51) · 16,112 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.24 (1.36 to 5.12) · 9,218 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 2.56 (1.28 to 3.83) · 9,540 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.097 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.529 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.7 (3.1 to 4.4) · 2,678 cases | Better | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.5 (9.1 to 12.3) · 10,521 cases | Better | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.7 to 0.8) · 6,063 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.48 (0.95 to 2.01) · 9,995 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 331 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.2 · 532 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 6.7 · 547 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.2 · 2,910 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 8 · 4,115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 7.4 · 1,351 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 1.6 · 23,286 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0.01 to 0.24) · 48,461 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.12 to 0.34) · 50,693 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0.66 to 2.11) · 9,390 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.79 (0.99 to 2.59) · 12,979 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.62 (0.53 to 2.72) · 3,510 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.38 to 0.82) · 40,829 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.8 · 3,298 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.091 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.859 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.3 · 667 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 18.7 · 4,060 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -23.8 · 603 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.8 · 3,334 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.5 · 4,338 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 5,069 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 3.7 · 3,383 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 6.8 · 386 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 820 cases | None | Jul 2023 – Jun 2025 |
What patients said (10,034 patients answered, 23% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Medicaid work
$1,461 in 2021
Medicaid paid $1,461 for 38 billed services this clinician did in 2021, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 13 | $804 |
| Short return visit (20+ min) | 25 | $657 |
| 2021 | 38 | 2 | 13 | $1,461 |
| 2020 | 26 | 1 | 12 | $718 |
| 2019 | 12 | 1 | 12 | $307 |
See the largest Medicaid services in earlier years
2020
| Short return visit (20+ min) | 26 | $718 |
2019
| Short return visit (20+ min) | 12 | $307 |
Drugs they prescribed that Part D paid
$24,745
Pharmacies billed $24,745 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
23 generic and fewer than 11 brand-name prescriptions · $24,745 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 24 | 11 | None | None | $24,745 |
| 2022 | 60 | 18 | 0% (0) | None | $7,913 |
| 2021 | 104 | 23 | None | 20% | $26,024 |
| 2020 | 71 | 24 | None | 21% | $53,807 |
| 2019 | 124 | 29 | None | None | $260,883 |
| 2018 | 145 | 38 | None | None | $83,597 |
| 2017 | 46 | None | None | None | $3,544 |
| 2016 | 26 | 14 | None | None | $260 |
| 2014 | 18 | None | None | None | $904 |
| 2013 | 39 | 15 | None | 51% | $2,152 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 3 drugs
| Eliquis | 14 | $7,441 | $531 |
| Ondansetron | 18 | $277 | $15 |
| Metoclopramide | 13 | $22 | $2 |
2020: 1 drug
| Eliquis | 11 | $5,477 | $498 |
2019: 2 drugs
| Afinitor | 15 | $248,445 | $16,563 |
| Ondansetron | 13 | $49 | $4 |
2018: 3 drugs
| Ondansetron | 14 | $265 | $19 |
| Ibuprofen | 17 | $76 | $4 |
| Metoclopramide | 12 | $53 | $4 |
2013: 1 drug
| Jolivette | 11 | $248 | $23 |
Money from drug and device companies
$51 in 2025
| 2025 | 2 | 2 | None | $51 |
| 2024 | 1 | 1 | None | $17 |
| 2021 | 3 | 4 | $8,057 | $8,057 |
| 2020 | 1 | 1 | $1,300 | $1,300 |
| 2019 | 3 | 6 | $2,000 | $2,247 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Karyopharm Therapeutics | Xpovio | $33 | 1 payment
|
| Vertex Pharmaceuticals | Journavx | $18 | 1 payment
|
See all 2 published payments
| Karyopharm Therapeutics | Meals · 2025-05-30 | Xpovio | $33 |
| Vertex Pharmaceuticals | Meals · 2025-02-25 | Journavx | $18 |
See earlier years (2024, 2021, 2020, 2019)
2024: $17
| Vertex Pharmaceuticals | None | $17 | 1 payment
|
2021: $8,057
| GlaxoSmithKline | Zejula | $5,200 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $2,167 | 1 payment
|
| EMD Serono | None | $690 | 1 payment
|
2020: $1,300
| GlaxoSmithKline | Zejula | $1,300 | 1 payment
|
2019: $2,247
| Clovis Oncology | Rubraca | $2,101 | 3 payments
|
| Merck Sharp & Dohme | Lynparza | $130 | 2 payments
|
| Tesaro | Zejula | $17 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| TESARO, Inc. · Phase 2 Multicohort Study To Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer Opal · 2019 | Their institution | $345,953 |
| GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2022 | Their institution | $156,829 |
| EMD Serono, Inc. · Safety Study of Bintrafusp Alfa in Combination With Platinum + Paclitaxel Bevacizumab and Bintrafusp Alfa in Combination With Platinum + Radiation Therapy in Participants With Advanced Cervical Cancer · 2021 | Their institution | $143,231 |
| GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2024 | Their institution | $117,564 |
| GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2021 | Their institution | $86,124 |
| GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2020 | Their institution | $27,650 |
| GlaxoSmithKline, LLC. · Phase 2 Multicohort Study To Evaluate the Safety and Efficacy of Novel · 2020 | Their institution | $9,653 |
| GlaxoSmithKline, LLC. · A Phase 1b/2 Multicohort Umbrella Study To Evaluate the Safety and Eff · 2022 | Their institution | $8,757 |
| GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2025 | Their institution | $6,662 |
| GlaxoSmithKline, LLC. · A Phase 1b/2 Multicohort Umbrella Study To Evaluate the Safety and Eff · 2021 | Their institution | $2,005 |
Professional record
- NPI
- 1467776948
- Licence
- CA 149779California A149779: Delinquent · expires 2025-05-31
- Group
- New York University
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207VX0201X (207VX0201X)
- Mailing address
- 900 Blake Wilbur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2010-03-26
- NPI last updated
- 2017-08-07
This is when the NPI record was last certified, not a medical board exam.